Loading…

Loading grant details…

Active NON-SBIR/STTR RPGS NIH (US)

Role of plasma cells in chronic rejection after lung transplantation

$7.47M USD

Funder NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Recipient Organization University of Pittsburgh At Pittsburgh
Country United States
Start Date Sep 02, 2024
End Date May 31, 2028
Duration 1,367 days
Number of Grantees 2
Roles Co-Investigator; Principal Investigator
Data Source NIH (US)
Grant ID 10999544
Grant Description

SUMMARY Lung transplantation (LTx) is the only life-saving intervention for many patients with end-stage lung disease. The long-term survival after LTx, however, is severely limited primarily due to chronic rejection of the allograft (chronic lung allograft dysfunction - CLAD). Bronchiolitis obliterans syndrome (BOS) is the most frequent phenotype of CLAD. It is characterized by partial

to complete obliteration and luminal occlusion of distal airways and includes features of subepithelial cellular inflammation, peribronchial and interstitial fibrosis, and selective loss of club cells within the airway epithelium. The pathogenesis of CLAD remains poorly understood, largely due to a lack of clinically relevant animal models, but includes influx and activation of cell

populations of the innate and acquired immune system, tissue remodelling, and distorted immune- epithelial cell crosstalk. However, which specific immune cell populations drive tissue remodelling in the transplanted lung remains unknown. We have recently discovered a significant increase in B cell populations and Marginal Zone B And B1 Cell Specific Protein (MZB) 1-positive plasma

cells in rejected lungs, both in lungs from a novel mouse model of chronic rejection after orthotopic LTx, as well as in retransplanted CLAD patients. We showed that an innate-like B-1B population served as a progenitor pool of MZB1+ plasma cells and that B cell deficiency prevented chronic rejection in mice. Systemic depletion of B cells, however, is associated with increased risks of

concomitant infections, in particular in patients routinely receiving high doses of immunosuppressive regimen, such as LTx patients, thus requiring more nuanced approaches to modify this pathogenic B and plasma cell populations. Therefore, the overarching goal of this application is to define the spatiotemporal profile and cellular heterogeneity of MZB1+ B and

plasma cell populations over time after LTx and interrogate their mechanistic contribution to chronic rejection by manipulation their abundance and function in vivo. We hypothesize that plasma cells accumulate in chronically rejected lungs in peribronchial regions and cause increased peribronchial fibrosis and decreased lung function in chronic rejection. To test this

hypothesis, we propose the following aims: Aim 1: To provide a comprehensive and detailed map of B and plasma cell gene expression profiles, population heterogeneity, and temporal dynamics in the chronically rejected lung after LTx. Aim 2: To mechanistically interrogate whether deletion of MZB1 or blocking the differentiation of MZB1+ plasma cells from B-1B cells prevents tissue

fibrosis, lung function deterioration, and chronic rejection after orthotopic LTx in mice.

All Grantees

University of Pittsburgh At Pittsburgh

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant